U.S. markets closed

AnaptysBio, Inc. (AN6.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
23.24-0.07 (-0.30%)
At close: 7:55PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close23.31
Bid0.00 x 0
Ask0.00 x 0
Day's Range22.93 - 23.66
52 Week Range11.49 - 29.09
Avg. Volume2
Market Cap632.858M
Beta (5Y Monthly)0.12
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Why AnaptysBio Was a Stock Market Star on Friday
      Motley Fool

      Why AnaptysBio Was a Stock Market Star on Friday

      What happened AnaptysBio (NASDAQ: ANAB) closed more than 10% higher on Friday. This followed news that a drug the company partnered on has received a positive opinion from an important multinational health agency.

    • Why AnaptysBio Fell by as Much as 10% Today
      Motley Fool

      Why AnaptysBio Fell by as Much as 10% Today

      On Tuesday, AnaptysBio (NASDAQ: ANAB) traded down nearly 10% at one point, before recovering to end the day 2.5% higher. There wasn't any direct news driving such sentiments; rather, it seems other factors were at play. AnaptysBio is a clinical-stage biotech that concentrates on immunology therapies -- currently a hot area of development in the healthcare world.

    • Why AnaptysBio Trounced the Market on Thursday
      Motley Fool

      Why AnaptysBio Trounced the Market on Thursday

      AnaptysBio (NASDAQ: ANAB) rose by just over 11% on Thursday, as a high-profile bank has become more optimistic on the stock, to put it lightly. J.P. Morgan analyst Anupam Rama upgraded his recommendation on AnaptysBio stock. Rama is basing his enthusiasm on the company's upcoming official data release for its phase 2 clinical trial of imsidolimab.